A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03034915 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

2696

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: UMEC/VI 62.5/25 mcg via ELLIPTA
DRUG: UMEC 62.5 mcg via ELLIPTA
DRUG: Salmeterol 50 mcg via DISKUS
DRUG: Placebo via ELLIPTA
DRUG: Placebo via DISKUS

Sponsor

GlaxoSmithKline